UAE Announces voluntary Recall of Nestlé Infant Formula Products
Table of Contents
A precautionary recall of select Nestlé infant formula products has been initiated in the United Arab Emirates following the detection of traces of Bacillus cereus in a raw material used during production. The recall, announced jointly by the Emirates Drug Establishment (EDE) and Nestlé, underscores a commitment to stringent safety standards for vulnerable populations.
The recall affects a limited number of batches of NAN Comfort 1, NAN OPTIPRO 1, NAN SUPREME PRO 1, 2, 3, S-26 Ultima 1, 2, 3, and Alfamino infant formula. According to the EDE, the identified raw material contained the bacteria, which has the potential to produce the toxin cereulide.
“Product safety and quality, particularly when it comes to children’s health, is our highest priority,” a senior official stated. To date, authorities have confirmed that no illnesses or adverse events have been linked to the affected batches. All other Nestlé products currently available for purchase remain safe for consumption.
Proactive Measures to Safeguard Public Health
The EDE and Nestlé are working in close coordination to swiftly remove the potentially affected products from the market.Affected batches have already been quarantined in both the company’s and distributors’ warehouses. Efforts are underway to complete the recall process, adhering to established regulatory procedures.
The recall extends to all points of sale,including online retail platforms,ensuring comprehensive removal of the impacted products. This coordinated approach demonstrates the UAE’s robust pharmaceutical security system and its ability to respond effectively to potential risks.
Strengthening Pharmaceutical Security in the UAE
This incident highlights the EDE’s commitment to reinforcing the national pharmaceutical security system. The Establishment operates a comprehensive regulatory framework based on proactive risk assessment and continuous monitoring of both local and global pharmaceutical supply chains.
“These measures were undertaken to protect public health and safety,” the EDE confirmed in a release. The swift action taken reflects the country’s dedication to ensuring the sustainable availability of medical products at the highest standards of quality and safety. The EDE’s framework enhances the nation’s capacity to respond rapidly to any incident that could compromise the safety or availability of essential medications.
Why: A precautionary recall was initiated due to the detection of traces of Bacillus cereus in a raw material used to produce select Nestlé infant formula products. The bacteria has the potential to produce the toxin cereulide.
Who: The recall was announced jointly by the Emirates Drug Establishment (EDE) and Nestlé. It affects consumers in the United Arab Emirates who purchased the specified batches of infant formula.
What: The recall encompasses a limited number of batches of NAN Comfort 1, NAN OPTIPRO 1, NAN SUPREME PRO 1, 2, 3, S-26 Ultima 1, 2, 3, and Alfamino infant formula.
How did it end?: The EDE and Nestlé are coordinating to quarantine affected batches in warehouses and remove them from all points of sale, including online platforms.As of the release, no illnesses have been linked to the affected products, and the recall is ongoing to ensure complete removal.The EDE is using this incident to reinforce its pharmaceutical security system.
